Of the 71 patients who were treated with concurrent oxaliplatin-containing chemotherapy, all had tumours with either a confirmed wild-type RAS or KRAS mutation status before their first dose of panitumumab (Table 4). This evidence concerns the gene KRAS and neoplasm.